New drug development is a highly regulated and complex process that involves the pharmaceutical industry, academic institutions, and government agencies' collaborative work. In pre-clinical testing, statistics indicate that out of 5000 compounds only five enter and evaluated in human clinical trials, moreover, only one drug is approved for human use. The whole process of drug development takes around $2-2.5 billion and a time of 12-15 years to complete. Around 50 % of investigational compounds fail during the development phase of clinical trials. Despite numerous scientific, technological advancements in research and development, many clinical trials fail to develop new, safe, and effective drugs. Approximately 70% of clinical trials fail in phase 2 whereas; the failure rate of confirmatory trials (phase 3) is around 50%. Tufts center for the study of drug development evaluated the three most common factors behind clinical trial failure- safety, efficacy, and deficient funds. Success-failure of a trial is also associated with other factors like a new molecule, molecular size, and therapeutic efficacy. As drug development involves numerous lives and billions of investments, one failed trial affects the subject’s quality of life by physical/social consequences and huge losses to pharmaceutical companies. To reduce the failure rate, many biopharmaceutical companies have opted or established their own more disciplined protocol, portfolio, and progress review frameworks. These strategies reduce the chances of errors during drug development and help in clinical trials' success rate.
1. Barclay SC. What is restorative dentistry? 2017. pp. 5-7.
2. Martin N, Shahrbaf S, Towers A, Stokes C, Storey C. Remote clinical consultations in restorative dentistry: a clinical service evaluation study. Br Dent J. 2020;228(6):441-7.
3. Kalsi AS, Kochhar S, Lewis NJ, Hemmings KW. New UK graduates' knowledge of training and service provision within restorative dentistry–a survey. Br Dent J. 2017;222(11):881-7.
4. Schnabl D, Guarda A, Guarda M, von Spreckelsen LM, Riedmann M, Steiner R, et al. Dental treatment under general anesthesia in adults with special needs at the University Hospital of Dental Prosthetics and Restorative Dentistry of Innsbruck, Austria: a retrospective study of 12 years. Clin Oral Investig. 2019;23(11):4157-62.
5. Husein AB, Butterworth CJ, Ranka MS, Kwasnicki A, Rogers SN. A survey of general dental practitioners in the North West of England concerning the dental care of patients following head and neck radiotherapy. Prim Dent Care. 2011;(2):59-65.
6. Hajisadeghi S, Kashani Z. Survey of patients satisfaction in the faculty of dentistry, Qom university of medical sciences in 2016-2017. Qom Univ Med Sci J. 2018;12(2):62-73.
7. Arrow P, Forrest H. Atraumatic restorative treatments reduce the need for dental general anaesthesia: a non‐inferiority randomized, controlled trial. Aust Dent J. 2020;65(2):158-67.
8. Li X, Mak CM, Ma KW, Wong HM. Restoration of dental services after COVID-19: The fallow time determination with laser light scattering. Sustain Cities Soc. 2021;74:103134.
9. Wilson PH, Boyle CA, Smith BJ. Conscious sedation training received by specialist registrars in restorative dentistry in the UK: a survey. Br Dent J. 2006;201(6):373-7.